⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 4, 2022Annals of Internal MedicineOpen Access

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Follmann et al. (2022) studied this question.

synapsesocial.com/papers/69d9adee8fbc15f99e684234 https://doi.org/10.7326/m22-1300

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and OmicronOriginal Research · 2022 · 83 citations
2Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE TrialLate-Phase Clinical Trial · 2021 · 7 citations
3Predictors of Nonseroconversion after SARS-CoV-2 InfectionOriginal Research · 2021 · 67 citations
4SARS-CoV-2 Transmission From People Without COVID-19 SymptomsDecision Analysis · 2021 · 1,114 citations
5SARS-CoV-2 transmission risk from asymptomatic carriers: Results from a mass screening programme in LuxembourgOriginal Research · 2021 · 102 citations